Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Resource Type
Article
Authors
Yang, James Chih-Hsin ; Wu, Yi-Long ; Schuler, Martin ; Sebastian, Martin ; Popat, Sanjay ; Yamamoto, Nobuyuki ; Zhou, Caicun ; Hu, Cheng-Ping ; O'Byrne, Kenneth ; Feng, Jifeng ; Lu, Shun ; Huang, Yunchao ; Geater, Sarayut L ; Lee, Kye Young ; Tsai, Chun-Ming ; Gorbunova, Vera ; Hirsh, Vera ; Bennouna, Jaafar ; Orlov, Sergey ; Mok, Tony ; Boyer, Michael ; Su, Wu-Chou ; Lee, Ki Hyeong ; Kato, Terufumi ; Massey, Dan ; Shahidi, Mehdi ; Zazulina, Victoria ; Sequist, Lecia V
Source
In Lancet Oncology February 2015 16(2):141-151
Subject
Primary Research Articles
Language
ISSN
1470-2045